ArticleTheranostics2018
Targeting Tumor Hypoxia Using Nanoparticle-engineered CXCR4-overexpressing Adipose-derived Stem Cells.
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Article
- Engineering MSC Migration: Roles of Nanoparticles in Activating Migratory Pathways and Functions.International journal of molecular sciences · 2026Review
- An osteosarcoma-on-a-chip model for studying osteosarcoma matrix-cell interactions and drug responses.Bioactive materials · 2024Article
- Chemokines in the tumor microenvironment: implications for lung cancer and immunotherapy.Frontiers in immunology · 2024Review
- Monitoring Cell Proliferation by Dye Dilution: Considerations for Panel Design.Methods in molecular biology (Clifton, N.J.) · 2024Review
- Alleviation of Angiotensin II-Induced Vascular Endothelial Cell Injury Through Long Non-coding RNA TUG1 Inhibition.Combinatorial chemistry & high throughput screening · 2024Article
- Living Cells and Cell-Derived Vesicles: A Trojan Horse Technique for Brain Delivery.Pharmaceutics · 2023Review
- Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.Molecules (Basel, Switzerland) · 2023Review
- Nanoparticle elasticity regulates the formation of cell membrane-coated nanoparticles and their nano-bio interactions.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Mesenchymal stem cell therapy for neurological disorders: The light or the dark side of the force?Frontiers in bioengineering and biotechnology · 2023Review
- Mechanosensitive Ion Channel PIEZO1 Signaling in the Hall-Marks of Cancer: Structure and Functions.Cancers · 2022Review
- Nanotechnology-Based Combinatorial Anti-Glioblastoma Therapies: Moving from Terminal to Treatable.Pharmaceutics · 2022Review
- Tumor-penetrating peptide internalizing RGD enhances radiotherapy efficacy through reducing tumor hypoxia.Cancer science · 2022Article
- Firing up the Tumor Microenvironment with Nanoparticle-Based Therapies.Pharmaceutics · 2021Review
- Review
- The Role of Biomimetic Hypoxia on Cancer Cell Behaviour in 3D Models: A Systematic Review.Cancers · 2021Review
- Glioma stem cells and their roles within the hypoxic tumor microenvironment.Theranostics · 2021Review
- Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours.Cell proliferation · 2020Review
- Cell-Based Nanoparticles Delivery Systems for Targeted Cancer Therapy: Lessons from Anti-Angiogenesis Treatments.Molecules (Basel, Switzerland) · 2020Review
- Two-dimensional nanomaterials beyond graphene for antibacterial applications: current progress and future perspectives.Theranostics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hypoxia, a hallmark of malignant tumors, often correlates with increasing tumor aggressiveness and poor treatment outcomes. Due to a lack of vasculature, effective drug delivery to hypoxic tumor regions remains challenging. Signaling through the chemokine SDF-1α and its receptor CXCR4 plays a critical role in the homing of stem cells to ischemia for potential use as drug-delivery vehicles. To harness this mechanism for targeting tumor hypoxia, we developed polymeric nanoparticle-induced CXCR4-overexpressing human adipose-derived stem cells (hADSCs). Using glioblastoma multiforme (GBM) as a model tumor, we evaluated the ability of CXCR4-overexpressing hADSCs to target tumor hypoxia in vitro using a 2D migration assay and a 3D collagen hydrogel model. Compared to untransfected hADSCs, CXCR4-overexpressing hADSCs showed enhanced migration in response to hypoxia and penetrated the hypoxic core within tumor spheres. When injected in the contralateral brain in a mouse intracranial GBM xenograft, CXCR4-overexpressing hADSCs exhibited long-range migration toward GBM and preferentially penetrated the hypoxic tumor core. Intravenous injection also led to effective targeting of tumor hypoxia in a subcutaneous tumor model. Together, these results validate polymeric nanoparticle-induced CXCR4-overexpressing hADSCs as a potent cellular vehicle for targeting tumor hypoxia, which may be broadly useful for enhancing drug delivery to various cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.